Publication details
RASmiR DEVELOPMENT SAFETY UPDATE REPORT Period covered: 1.8.2023– 31.5.2024
| Authors | |
|---|---|
| Year of publication | 2024 |
| Type | Research report |
| MU Faculty or unit | |
| web | RASMIR |
| Description | This is the fifth annual DSUR for the RASmiR trial summarising safety data received by the Sponsor from August 1, 2023 –May 31, 2024. Clinical trial RASmiR is a multicenter, open label, single-arm, phase II trial. During the period under review, 4 patients were enrolled to the study. The annual incidence of colorectal cancer (C18-C20) exceeds 8,000 cases in the Czech Republic. Metastases are detected in about 20 % of patients at the time of diagnosis (clinical stage IV), approximately another 25 % of patients will relapse after the primary curative treatment. In 2015, 1576 patients were newly diagnosed with metastatic colorectal cancer (mCRC) in the Czech Republic. Patients, who are candidates for palliative treatment, could be initially treated (1st line therapy) by combination of chemotherapy and targeted anticancer drugs (anti-VEGF or anti-EGFR) or by chemotherapy alone, if their condition does not allow for intensive treatment. |